Recent reports highlight the promising effects of novel immune cell therapies targeting IL13Ra2, such as bispecific T-cell engagers (BiTEs) and bispecific killer cell engagers (BiKEs), demonstrating their cytotoxicity against GBM, potentially showing more therapeutic potential than traditional immune cell therapies [35,36]. The gene discussed is IL13RA2; the disease is glioblastoma.